Redmile Group, LLC Adc Therapeutics Sa Transaction History
Redmile Group, LLC
- $1.53 Billion
- Q2 2024
A detailed history of Redmile Group, LLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Redmile Group, LLC holds 15,269,217 shares of ADCT stock, worth $41.2 Million. This represents 3.15% of its overall portfolio holdings.
Number of Shares
15,269,217
Previous 15,269,217
-0.0%
Holding current value
$41.2 Million
Previous $68.6 Million
29.62%
% of portfolio
3.15%
Previous 2.7%
Shares
14 transactions
Others Institutions Holding ADCT
# of Institutions
79Shares Held
52.9MCall Options Held
300KPut Options Held
59.3K-
Prosight Management, LP Dallas, TX9.57MShares$25.8 Million9.45% of portfolio
-
Orbimed Advisors LLC San Diego, CA4.32MShares$11.7 Million0.33% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$9.6 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.97MShares$8.01 Million0.0% of portfolio
-
Silverarc Capital Management, LLC1.77MShares$4.78 Million1.59% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $210M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...